Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020


The Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.


The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals.  This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:


  • Imaging
    • CT
    • Endoscope
    • Molecular and nuclear
      • PET
      • SPECT
    • MRI
    • Ultrasound
    • X ray
      • Angiography
      • Fluoroscopy
      • Mammography


This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2014.


This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2014. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements ( deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.


Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.


The initial chapters of this report provide an orientation of Diagnostic Imaging dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostic Imaging dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading Diagnostic Imaging deals since 2014. Deals are listed by headline value, signed by big pharma, most active Diagnostic Imaging dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostic Imaging dealmaking with a brief summary followed by a comprehensive listing of Diagnostic Imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


Chapter 5 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2014. The chapter is organized by specific Diagnostic Imaging technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided organized by Diagnostic Imaging partnering company A-Z, deal type definitions and Diagnostic Imaging partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostic Imaging partnering and dealmaking since 2014.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostic Imaging technologies and products.


Key benefits


Global Diagnostic Imaging Partnering Terms and Agreements provides the reader with the following key benefits:


  • In-depth understanding of diagnostic deal trends since 2014
  • Analysis of the structure of diagnostic agreements with numerous real life case studies
  • Comprehensive access to over 600 actual diagnostic imaging deals entered into by the world’s biopharma companies
  • Detailed access to actual diagnostic contracts enter into by the leading biopharma companies
  • Insight into the terms included in a diagnostic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Diagnostic Imaging Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic imaging trends and structure of deals entered into by leading companies worldwide.


Global Diagnostic Imaging Partnering Terms and Agreements includes:


  • Trends in diagnostic imaging dealmaking in the biopharma industry since 2014
  • Analysis of diagnostic imaging deal structure
  • Case studies of real-life diagnostic imaging deals
  • Access to over 600 diagnostic imaging contract documents
  • The leading diagnostic imaging deals by value since 2014
  • Most active diagnostic imaging  dealmakers since 2014
  • The leading diagnostic imaging partnering resources


In Global Diagnostic Imaging Partnering Terms and Agreements, the available contracts are listed by:


  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Specific technology target


Each deal title links to online deal records of actual diagnostic imaging partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. 


The Global Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive access to available contract documents for over 600 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise diagnostic rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:


  • In-depth understanding of diagnostic imaging deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of diagnostic imaging agreements with numerous real life case studies
  • Comprehensive access to over 600 actual diagnostic imaging deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual diagnostic imaging contracts entered into by themost active companies
  • Identify leading diagnostic imaging deals by value since 2014
  • Identify the most active diagnostic imaging dealmakers since 2014
  • Insight into the terms included in a diagnostic imaging agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Diagnostic Imaging dealmaking


2.1. Introduction
2.2. Diagnostic Imaging partnering over the years
2.3. Most active Diagnostic Imaging dealmakers
2.4. Diagnostic Imaging partnering by deal type
2.5. Diagnostic Imaging partnering by therapy area
2.6. Deal terms for Diagnostic Imaging partnering
2.6.1 Diagnostic Imaging partnering headline values
2.6.2 Diagnostic Imaging deal upfront payments
2.6.3 Diagnostic Imaging deal milestone payments
2.6.4 Diagnostic Imaging royalty rates


Chapter 3 – Leading Diagnostic Imaging deals


3.1. Introduction
3.2. Top Diagnostic Imaging deals by value


Chapter 4 – Most active Diagnostic Imaging dealmakers


4.1. Introduction
4.2. Most active Diagnostic Imaging dealmakers
4.3. Most active Diagnostic Imaging partnering company profiles


Chapter 5 – Diagnostic Imaging contracts dealmaking directory


5.1. Introduction
5.2. Diagnostic Imaging contracts dealmaking directory


Chapter 6 – Diagnostic Imaging dealmaking by technology type


Chapter 7 – Partnering resource center


7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking



Appendix 1 – Diagnostic Imaging deals by company A-Z


Appendix 2 – Diagnostic Imaging deals by stage of development


Phase I
Phase II
Phase III


Appendix 3 – Diagnostic Imaging deals by deal type


Asset purchase
Bigpharma outlicensing
Collaborative R&D
Equity purchase
Joint venture
Manufacturing - OEM
Spin out
Technology transfer


Appendix 4 – Diagnostic Imaging deals by therapy area


Central Nervous System
Genetic disorders
Hospital care
Orphan disease


Appendix 5 –Deal type definitions


About Wildwood Ventures


Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures


Figure 1: Diagnostic Imaging partnering since 2014
Figure 2: Active Diagnostic Imaging dealmaking activity– 2014 to 2020
Figure 3: Diagnostic Imaging partnering by deal type since 2014
Figure 4: Diagnostic Imaging partnering by disease type since 2014
Figure 5: Diagnostic Imaging deals with a headline value
Figure 6: Diagnostic Imaging deals with an upfront value
Figure 7: Diagnostic Imaging deals with a milestone value
Figure 8: Diagnostic Imaging deals with a royalty rate value
Figure 9: Top Diagnostic Imaging deals by value since 2014
Figure 10: Most active Diagnostic Imaging dealmakers 2014 to 20120
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3DR Labs, 7D Surgical, A*STAR Agency for Science, Technology and Research, AAM Healthcare, Abbott Laboratories, Abbvie, Abcam, Acacia Research, Accudata Systems, Accuray, AC Immune, Acoustic MedSystems, Actelion, Acutus Medical, AdAlta, Adaptiiv, Advanced Accelerator Applications, Advanced Animal Diagnostics, Advanced Cell Diagnostics, Advanced Chemistry Development, Advanced Guidance Technologies, Advanced Nuclear Medicine Ingredients, Agfa HealthCare, Agilent Technologies, AG Mednet, Aiforia Technologies, AI Metrics, AIM Specialty Health, Aircraft Medical, Akili Interactive Labs, Albany Molecular Research, Albert Einstein Healthcare Network, Alector, Alibaba Health, Align Technology, Allegheny Technologies, Allergan, Allied Healthcare Products, Alphaeon, Alpha Imaging, Alpinion Medical Systems, Alteris, Altris, Alzheimer's Association, Alzheimers Research UK, Ambry Genetics, AmCad BioMed, A Menarini Diagnostics, American Health Imaging, American Medical Systems, Amerinet, Amos Gazit, AMRA, AMRA Medical, Amydis Diagnostics, Analogic, Analytics 4 Life, Antaros Medical, Applied Medical, APRINOIA Therapeutics, Arc Medical Design, Arivis, Artialis, ARTMS Product, ARUP Laboratories, Aspect Imaging, AstraZeneca, Austin Health, Auxogyn, Avantis Medical Systems, Aytu BioScience, Banner Health, Bayer, Bay Labs, Baylor College of Medicine, BC Technical, BioArctic Neuroscience, Biogen, Biopsy Sciences, Bioscience Pharma Partners, Biotechnology Innovation Organization, BioTelemetry, Bioverativ, BJC HealthCare, Blackford, Blue Earth Diagnostics, Boehringer Ingelheim, BostonGene, Boston Scientific, Bpifrance, Bracco Diagnostics, Bracco Imaging, BRAIN Initiative, BrainLAB, BrainScope, Brigham and Women's Hospital, Broad Institute, Bruker, Bruker AXS, Bruker Energy & Supercon Technologies (BEST), Butantan Institute, BWX Technologies, C&C Irradiator Service, C4 Imaging, Calcivis, Caliber Imaging & Diagnostics, Canadian Teleradiology Services, Cancer Prevention and Research Institute of Texas, Cancer Targeted Technology, Canon, Canon Lifecare Solutions, Cantel Medical, Capital X-ray, Caprion Proteomics, CapsoVision, Cardinal Health, CardioCORE Lab, Cardiowise, CareFusion, Carestream Health, Carl Zeiss, CarThera, Case Western Reserve University, Catholic University Leuven, CBD Solutions, Celgene, CellSight Technologies, Celsion, Celtic Biotech, Centerline Biomedical, Centre for Addiction and Mental Health, Centre for Imaging Technology Commercialization, Centre for Probe Development and Commercialization, Centre for Structural Systems Biology, CerebraCell, CereHealth, Ceres, Cerevast Therapeutics, Cerveau Technologies, Champalimaud Foundation, Check-Cap, ChemImage, Children's Hospital Boston, Children's National Health System, China Development Industrial Bank, China Grand Pharmaceutical, Chindex Medical Limited, Chip-Man Technologies, Cimar, Cincinnati Children’s Hospital Medical Center, City of Hope, Clarity Pharmaceuticals, Clear Guide Medical, ClearLight Diagnostics, ClearView Diagnostics, Cleveland Clinic, Client Outlook, Clinical Imaging Research Centre, Clinipace Worldwide, Cohen Veterans Bioscience, Colorado State University, Columbia University, Comanche County Memorial Hospital, Community Medical Center, Compact Imaging, Conavi Medical, ConBio (Shanghai), Confo Therapeutics, Connecticut Innovations, ContextVision, ContraVir Pharmaceuticals, Cook Medical, CorTechs Labs, CR Kennedy & Company, CrossBay Medical, CS Medical, CureMetrix, Curium, CurveBeam, CyberKnife, Cyclopharm, CymaBay Therapeutics, D&K Technologies, Dana-Farber Cancer Institute, Decathlon Capital Partners, Dectris, Deep Cube, Defense Advanced Research Projects Agency, Defense Logistics Agency, Definiens, Dehaier Medical Systems, Densitas, Department of Defense, Department of Veterans Affairs, DePuy, DermSpectra, Desert Imaging, Deutsches Elektronen-Synchrotron, Device Technologies, Devicor Medical Products, DiA Imaging Analysis, DICOM Grid, Dicom Systems, Digisonics, Dilon Diagnostics, Disior, Domainex, Duke-NUS Graduate Medical School Singapore, Duke University, Duke University Medical Center, Duquesne University, DySIS Medical, E.I. Medical Imaging, Echosens, Eckert & Ziegler, Edan Instruments, Edinburgh Molecular Imaging, Edwards Lifesciences, Eigen, Eisai, eKare, Eko, Electrical Geodesics, Elekta, Eli Lilly, ElMindA, Emory University, EMTensor, EndoChoice, ENDRA Life Sciences, Enigma Biomedical, Entellus Medical, EOS Imaging, EpiBone, Epica Medical Innovations, Epsilon, ERT, Esaote, Eureka Eurostars, European Prevention of Alzheimer’s dementia Initiative (EPAD), Event Cardio Group, Exact Imaging, Exact Sciences, Expesicor, Faes Farma, Faron Pharmaceuticals, FASTVet, FEI, Finnish Funding Agency for Technology and Innovation (TEKES), Flagship Biosciences, FlexDex, Fluidigm, Focal Healthcare, Food and Drug Administration (FDA), FORMA Therapeutics, Frankenman Medical Equipment, frog, Fujifilm, Fujifilm medical systems, FUJIFILM SonoSite, Fulcrum Therapeutics, Fusion Antibodies, Fuzionaire Diagnostics, Gamma Medica, GCS Sesan, GE Healthcare, General Electric (GE), GenesisCare, Geneva University Hospitals, Genomac Research Institute, Geo-Med, German Cancer Research Center, Gestalt Diagnostics, GlaxoSmithKline, Global Genomics Group, Global Medical Solutions, gMed Canada, Goodwin Biotechnology, Google, Guerbet, Guided Therapeutics, Guided Therapy Systems, Hadassah Medical Center, Hainan Sinotau Pharmaceutical, Halo Dx, Halt Medical, Hamilton Health Sciences, Harvard Medical School, HealthCare Konnect, HealthLytix, Healthmark Industries, HealthMyne, HealthSpot, HealthTrust, Heartflow, Heart Imaging Technologies, HeartIT, HeartScore, Hennepin County Medical Center, Henry Ford Health System, Henry Schein, Heritage Valley Health System, HistoIndex, Hitachi, Hitachi Aloka Medical, Hitachi Medical Systems Europe, Hologic, Horizon 2020, Hospital Services, HOYA Vision Care, HP, HR Pharmaceuticals, Human Longevity, HuminTec, Hunan Xing Hang Rui Kang Bio-Technologies, Huvitz, Hybridyne Imaging Technologies, Hyperfine Research, i-Optics, IBA, IBA Molecular Imaging, Ibex Medical Analytics, IBM, IBM Watson Health, iCAD, Icagen, Icometrix, ICT Health, IDS, Ifa Systems, ImaBiotech, Image Analysis, ImageIQ, Image Stream Medical, ImaginAb, Imaging Associates, Imago Systems, Imalogix, Imanova, IMD Companies, ImmersiveTouch, iMotions, Imperial College London, Imperial Innovations, Imricor Medical Systems, IMRIS, Indiana University, Indica Labs, Inflazome, InfraReDx, InfraScan, Ingenza, inHEART, InnerOptic Technology, Inscopix, InSightec, Institut de Radiofarmacia Aplicada de Barcelona, Intermountain Healthcare, IntroMedic, inVentiv Health, inviCRO, IQ-AI, iSchemaView, ISIS Innovation, Isologic Innovative Radiopharmaceuticals, Isotope Technologies Garching, Isotopia Molecular Imaging, ITEL, Item, ITEM Medical Technologies, iThera Medical, ITM Isotopen Technologien, iVu Imaging, IXICO, James S. McDonnell Foundation, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, Johns Hopkins University, Jubilant DraxImage, Kanteron Systems, Karolinska University Hospital, Keck School of Medicine of USC, Kennedy Health System, Kent Imaging, Kiyatec, Konica Minolta, Korea Pharma, KUB Technologies, Laerdal Medical, Lantheus Holding, Lantheus Medical Imaging, Lehigh University, Leica Biosystems, Leica Microsystems, Leiden University, LeMaitre Vascular, LEO Pharma, LI-COR Biosciences, Life Image, Lightpoint Medical, LKC Technologies, LumaMed, Lumicell, Lumiphore, Lunaphore, Lundbeck, Lunit, M2i, MabVax Therapeutics, Macquarie University, Magellan Health Services, Magic Leap, Magnetic Insight, Major Health Partners, Mallinckrodt Pharmaceuticals, Manhattan Scientifics, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Materialise, Mauna Kea Technologies, Mavig, Mayo Clinic, McGill University, MD Anderson Cancer Center, Medassets, MedCom, MEDIAN Technologies, Medical Equipment Solutions, Medical Imaging, Medic Vision, Medidata Solutions, Medigus, Medimaps Group, MED Institute, Mediso, Medpace, medPhoton, MedQuest, Medtronic, MedyMatch, MELA Sciences, MemorialCare Health System, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck Serono, Merge Healthcare, Merit Medical Systems, Merz, Metaoptima Technology, Methodist Hospital Houston, Mevion Medical Systems, Michael J Fox Foundation, Microsoft, MILabs, Mimetas, MindPeak, Mindray Medical International, Minimally Invasive Devices, Ministry of Health (Turkey), Minogue Medical, Minomic, MinXray, Misonix, Mission Health, Mitsubishi Chemical Corporation, Mizuho, Mobius Imaging, Molecular Devices, MolecularMD, MolecuLight, Molnlycke Health Care, Monteris Medical, Montreal Neurological Institute-Hospital, MRI Interventions, MR Solutions, n3D Biosciences, Nanjing Micro-Tech, Nano-X Imaging, nanoPET Pharma, NASA, National Cancer Institute, National Cancer Institute of Mexico, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Healthcare Services (NHS), National Heart, Lung and Blood Institute, National Institute of Biomedical Imaging and Bioengineering, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institutes of Health, National Physical Laboratory, National Research Nuclear Center, National Science Foundation, National Space Biomedical Research Institute, Nationwide Imaging Services, Natus Medical, Navidea Biopharmaceuticals, Navigate Surgical Technologies, NCM, Nelson Laboratories, Nephros, NetScientific, Neuroelectrics, NeuroLogica, NeuroScience Associates, NeuroVision Imaging, Newmars Group, New York University, Nexstim, Nihon Medi-Physics, Nikon Instruments, Ninepoint Medical, Nipro Corporation, Nordicneurolab, Nordion, Norgenix Pharmaceuticals, Norgine, Norsk medisinsk syklotronsenter, Northeastern University, North Mississippi Health Services, NorthStar Medical Radioisotopes, Northwell Health, Northwestern Medicine Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Novadaq Technologies, NovAliX, Novant Health, Novartis, Nuance Healthcare, Nucleo de Bioensaios Biossintese e Ecofisiologia de Produtos Naturais, numares, Nvidia, nView Medical, NZ Technologies, Occlugel, Olympus, Omega Medical Imaging, OncoBeta, OncoNano Medicine, OncoVision, OnDemand 3D, One Lambda, ON Semiconductor, Optasia Medical, Optibrand, Optim, Optos, OrthoGrid Systems, Ortho Kinematics, Otsuka, Otsuka America Pharmaceutical, Owlstone Medical, P-cure, Panacea Pharmaceuticals, Paracelsus Clinics, Parker Hannifin, Patient-Centered Outcomes Research Institute (PCORI),, Peek Vision, Pentax, PerkinElmer, Perry Baromedical, PETNET Solutions, Pfizer, PharmaCare Management, PharmaVentures, Phase Holographic Imaging, Philips, Philips Healthcare, Phoenix Children’s Hospital, Physio-Control, Ping An Ventures, Piramal Imaging, Planmeca, Planmed, Poitiers University, Polarean Imaging, Premier Inc, Prime Healthcare Services, Princeton University, Profil Institute for Clinical Research, Profound Medical, Progenics Pharmaceuticals, ProNova, Protea Biosciences, Qualigen, Quality Electrodynamics, QuantalRF,, RadCore Labs, Radlink, RadNet, RAM-Tech, RAW, ReadCoor, ReCor Medical, RedHill Biopharma, Redlen Technologies, Resonance Health, RFPi, Riverside Research, RMD Instruments, Roche, Rosetta Genomics, ROTOP Pharmaka, Royal Philips Electronics, Rutgers University, Salix Pharmaceuticals, Salk Institute, Salud Digna, Sanuwave Health, Sarepta Therapeutics, Saromics, SciBase, Science Exchange, Scil Proteins, Scintica Instrumentation, Sectra, Seibersdorf Laboratories, Sensus Healthcare, SerenaGroup, Shanghai Pharmaceutical, Shared Medical Services, Sheikh Zayed Institute for Pediatric Surgical Innovation, Shimadzu, Shine Medical, Shriners Hospital for Children, Siemens, Siemens Healthcare, Siemens Healthineers, SignaBlok, Singapore Bioimaging Consortium, Sirona Direct, SkinCure Oncology, Small Business Innovation Research, Smart Medical Systems, Smilow Cancer Hospital at Yale-New Haven (SCH), Smith & Nephew, Sofie Biosciences, SolaranRx, Solis Mammography, Sono-Tek, SonoSim, Sonrgy, Sony Olympus Medical Solutions, Soricimed Biopharma, Sorin Group, SpePharm, SST Group, Stanford Health Care, Stanford University, Stanford University School of Medicine, StemoniX, Stereotaxis, Stockholm County Council, Stratis Medical, Stryker, Subtle Medical, Sumitomo Cryogenics, Sunnybrook Health Sciences Centre, Super Resolution Technologies, SuperSonic Imagine, Surgical Theater, Susan G. Komen for the Cure, Swiss Institute of Allergy and Asthma Research, Swixx Biopharma, Synaptive Medical, Syneron, SyntheticMR, T3 Labs, Takeda Pharmaceutical, Tau Consortium, Techcyte, Teledyne Technology, TeleMammography Specialists, Telik, Telix Pharmaceuticals, Temple University, Terason, Teva Pharmaceutical Industries, The Christie, The Joint Pathology Center, Theraclion, Theragnostics, Thiel Foundation, Thomas Jefferson University, Tissue Analytics, Tokyo Metropolitan Institute of Gerontology, Toronto Innovation Acceleration Partners, Toshiba America Medical Systems, Toshiba Medical Systems Corporation, Touchstone Medical Imaging, Tracey Technologies, Transcriptome Sciences, Translational Research Institute for Space Health, Trivitron Healthcare, Tromp Medical, TrovaGene, Tulane University, Turku PET Center, UBMD Orthopaedics, Ulthera, Ultivue, UltraSpect, Unetixs Vascular, Unified Women's Clinical Research, United Imaging Healthcare, United States Military Cancer Institute, University City Science Center, University College London, University of Alabama at Birmingham, University of Arizona, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Glasgow, University of Hong Kong, University of Kent, University of Konstanz, University of Leeds, University of Leuven, University of Louisville, University of Maryland, University of Massachusetts Medical School, University of Melbourne, University of Minnesota, University of North Texas Health Science Center, University of Oxford, University of Southampton, University of Strathclyde, University of Toronto, University of Tubingen, University of Utah, University of Washington, University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center (UWCCC), University of Zurich, Uppsala University, Uppsala University Hospital, US Government, US Radiology Specialists, VA Medical Center (VAMC), Vantage Endoscopy, Varex Imaging, Varian Medical Systems, Vasomedical, Velocity Medical Solutions, Verisante Technology, VIB, ViewRay, Virginia Tech Intellectual Properties, Virtual Imaging, VirtualScopics, Visaris Americas, Visikol, Vistinct, VisualDx, Vital Images, Vivid Medical, Vizient, Volpara Solutions, VuCOMP, VU Medical Center, WaferGen Biosystems, Wallace H. Coulter Foundation, Washington University in St Louis, Weill Cornell Medical College, Welch Allyn, WellSpan York Hospital, Westchester Medical Center Health Network, Weston Brain Institute, Whiterabbit, William Osler Health System, Women & Infants Hospital of Rhode Island, WorldCare Clinical, Xavier University of Louisiana, Xbrane Bioscience, Xerox, XLIM, Xoran Technologies, XRpro Sciences, Xstrahl, Yale School of Medicine, Yale University, Yokogawa Electric, York Instruments, York University, Zebra Medical Vision, Zecotek Photonics, Zenalux Biomedical, ZetrOZ, Ziehm Imaging, Zimmer Biomet, Zionexa, ZoBio, Zonare Medical Systems

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.